

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
4 June 2009 (04.06.2009)

PCT

(10) International Publication Number  
**WO 2009/070793 A1**

(51) International Patent Classification:  
A61B 18/18 (2006.01)

(21) International Application Number:  
PCT/US2008/085114

(22) International Filing Date:  
1 December 2008 (01.12.2008)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/991,049 29 November 2007 (29.11.2007) US

(71) Applicant (for all designated States except US):  
PLUROMED, INC. [US/US]; 25-K Olympia Avenue,  
Woburn, MA 01801 (US).

(72) Inventor; and

(75) Inventor/Applicant (for US only): VOGEL, Jean-Marie  
[FR/US]; Five Oak Meadow Road, Lincoln, MA 01773  
(US).

(74) Agents: GORDON, Dana M. et al.; Patent Group, Foley  
Hoag LLP, 155 Seaport Boulevard, Boston, MA 02210-  
2600 (US).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA,  
CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE,  
EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID,  
IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK,  
LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW,  
MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT,  
RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ,  
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM,  
ZW.

(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,  
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,  
FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL,  
NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG,  
CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:  
— with international search report



WO 2009/070793 A1

(54) Title: ENDOSCOPIC MUCOSAL RESECTIONING USING PURIFIED INVERSE THERMOSENSITIVE POLYMERS

(57) Abstract: One aspect of the invention relates to use of a composition comprising a purified inverse thermosensitive polymer in an endoscopic procedure for gastrointestinal mucosal resectioning in a mammal. Another aspect of the invention relates to a method of gastrointestinal mucosal resectioning, comprising administering submucosally to a region of a gastrointestinal mucosa in a mammal an effective amount of a composition comprising a purified inverse thermosensitive polymer; and surgically resecting said region of gastrointestinal mucosa. Yet another aspect of the invention relates to a kit for use in gastrointestinal endoscopic mucosal resectioning in a mammal, comprising a composition comprising a purified inverse thermosensitive polymer; a syringe; and instructions for use thereof.

---

***Endoscopic Mucosal Resectioning Using Purified  
Inverse Thermosensitive Polymers***

---

**Related Applications**

5            This application claims the benefit of priority to United States Provisional Patent Application serial number 60/991,049, filed November 29, 2007.

**Background of the Invention**

          Endoscopic mucosal resectioning (EMR) is acknowledged as a curative therapeutic modality in the treatment of early gastrointestinal cancers. Heretofore, submucosal  
10    injection with saline has been used to minimize complications during EMR. However, the duration of tissue elevation after saline injection is relatively short, and repeated injections are needed to perform EMR on large lesions. Notwithstanding the fact that solutions with high viscosity, such as hydroxypropyl methylcellulose (HPMC), have been used in EMR, an adequate solution to this problem has remained elusive.

**15    Summary of the Invention**

          One aspect of the invention relates to use of a composition comprising a purified inverse thermosensitive polymer in an endoscopic procedure for gastrointestinal mucosal resectioning. Another aspect of the invention relates to a method of gastrointestinal  
20    mucosal resectioning, comprising administering submucosally to a region of a gastrointestinal mucosa in a mammal an effective amount of a composition comprising a purified inverse thermosensitive polymer; and surgically resecting said region of gastrointestinal mucosa. Yet another aspect of the invention relates to a kit for use in gastrointestinal endoscopic mucosal resectioning, comprising a composition comprising a purified inverse thermosensitive polymer; a syringe; and instructions for use thereof.

**25    Brief Description of the Figures**

**Figure 1** depicts graphically the viscosities of LeGoo Endo (a 20-25% aqueous solution of purified poloxamer 237) and a 20% aqueous solution of unpurified poloxamer 407 as a function of temperature.

**Figure 2** depicts graphically the viscosities of LeGoo Endo (a 20-25% aqueous  
30    solution of purified poloxamer 237) and a 20% aqueous solution of unpurified poloxamer 407 as a function of temperature.

## Detailed Description of the Invention

Endoscopic mucosal resection (EMR) represents a major advance in minimally invasive surgery in the gastrointestinal tract. EMR is based on the concept that endoscopy provides visualization and access to the mucosa, the innermost lining of the gastrointestinal tract -- the site where most gastrointestinal cancers from the esophagus to the rectum have their origin. The method combines the therapeutic power of endoscopic surgery with the diagnostic power of pathology examination of resected tissue.

EMR first proliferated in Japan, where endoscopists were faced with a very high incidence of stomach cancer. This differs from most Western countries, including the United States, where colon cancer is a much more common disease. Most colon cancers arise in mucosal polyps, which project into the lumen of the colon, making them relatively easy to remove at endoscopy using wire loops to grasp the polyp base. The polyps are then excised with electric current, producing simultaneous cutting action and cauterization.

In contrast, in the stomach most cancers do not begin in polyps, but in only slightly elevated, flat, or slightly depressed mucosal dysplastic lesions. Such lesions are very difficult to grasp with a simple wire snare. Japanese endoscopists worked to develop a number of methods to elevate the diseased mucosal area so that snaring would be possible. Most of these techniques used fluid injection into the submucosa, the layer of the gastrointestinal tract immediately below the mucosa, to elevate the mucosa and allow it to be grasped with a snare. Unfortunately, the fluids used to date have not been optimal for the EMR because, for example, they are typically insufficiently viscous to provide a sufficiently durable, elevated surface. Were fluids available that were capable of providing the optimal durable, elevated mucosal surface, EMR could also be used effectively in the esophagus, where early cancer and premalignant dysplasia also tends to be nonpolypoid and flat, and also in the colon, where it can be used to assist in removal of both small and large flat or sessile polyps.

Unpurified inverse thermosensitive polymers could be considered for this indication, but unfortunately these polymers, which gel at body temperature, gel in the catheter used for injection because the catheter warms to body temperature soon after it is deployed within the colon or stomach.

Remarkably, a purified inverse thermosensitive polymer (LeGoo-endo<sup>TM</sup>), which displays a rapid reversible liquid to gel transition, has now been shown to be efficacious as a submucosal injection solution in *ex vivo* and *in vivo* porcine models of human endoscopic

gastrointestinal mucosal resectioning (EMR). The rapid reversible liquid to gel transition achieved as a result its purified nature allows LeGoo-endo to be liquid at room temperature and to gel only as it emerges from the catheter at the EMR site. The mucosal elevation obtained with LeGoo-endo<sup>TM</sup> was more durable than that obtained with other commonly used substances. Moreover, results with LeGoo-endo<sup>TM</sup> were not subject to significant variations in terms of size and consistency. LeGoo-endo<sup>TM</sup> performed well in *in vivo* colonic EMR. These results indicate that use of LeGoo-endo<sup>TM</sup> or other purified inverse thermosensitive polymers may increase the safety and efficiency of human EMR procedures.

10 In certain embodiments, the bleb (i.e., the gel that provides the mucosal elevation) formed *in vivo* from the purified inverse thermosensitive polymer persists for about 30-180 minutes, about 45-150 minutes, about 60-120 minutes, about 75-100 minutes, about 90 minutes, about 80 minutes, about 70 minutes, about 60 minutes, about 50 minutes, about 40 minutes, or about 30 minutes.

15 In order to obtain the aforementioned results it was necessary to develop a method of injecting through a catheter into the colon or stomach a purified inverse thermosensitive polymer solution that transitions to a gel at body temperature. Among the challenges overcome was the fact that because the catheter quickly reaches body temperature while resident inside the body, the purified inverse thermosensitive polymer will gel inside the catheter prior to reaching the desired site for EMR. For example, due to gel formation in the catheter manual injection by pushing on the plunger of a syringe connected to a catheter is not workable, nor is injection assisted with a mechanical injector at pressures lower than 1200 psi; further, pressures higher than 1200 psi are precluded because they are sufficient to burst any conventional catheter. In other words, the method is not workable if the purified inverse thermosensitive polymer gels in the catheter (i.e., prior to reaching the EMR site), and pressures that can be tolerated by conventional catheters are insufficient to deliver in fluid form the purified inverse thermosensitive polymer to the EMR site.

25 Remarkably, the delivery problems were solved with a system comprising a high-pressure needle catheter connected to a syringe filled with purified inverse thermosensitive polymer, wherein said high-pressure needle catheter is contained within an administration device (e.g., a syringe pump) that generates pressure on the plunger of the syringe through a manual (e.g., screw), electrical or pressurized-gas mechanism. The higher pressures available and tolerated using said system have two functions: (a) pushing the viscous fluid

through the catheter; and (b) allowing for a sufficiently rapid injection that purified inverse thermosensitive polymer entering the catheter from the room-temperature syringe constantly regulates the temperature of the catheter so that the polymer does not gel in the catheter during the residence time, and only gels after it emerges from the catheter and is brought into direct contact with the EMR site.

In sum, LeGoo-Endo -- denoted "PS137-25" in the Figures -- is an aqueous solution of purified poloxamer 237 with a viscosity at body temperature 3.9 times that of unpurified 20% poloxamer 407, allowing for the formation of a lasting bleb capable of withstanding the pressure exercised by the elastic mucosal membrane; moreover, the viscosities of LeGoo-Endo at 25 C and room temperature are less than a tenth of the viscosities of unpurified 20% poloxamer 407 at those temperatures, respectively, thereby preventing gel formation within the catheter during administration of LeGoo-Endo, in part because the catheter is continuously cooled by new LeGoo-Endo as it enters the catheter under pressure.

#### *Inverse Thermosensitive Polymers*

In general, the inverse thermosensitive polymers used in the methods of the invention, which become a gel at or about body temperature, can be injected into the patient's body in a liquid or soft gel form. The injected material once reaching body temperature undergoes a transition from a liquid or soft gel to a hard gel. The inverse thermosensitive polymers used in connection with the methods of the invention may comprise a block copolymer with inverse thermal gelation properties. In general, biocompatible, biodegradable block copolymers that exist as a gel at body temperature and a liquid at below body temperature may also be used according to the present invention. Also, the inverse thermosensitive polymer can include a therapeutic agent, such as anti-angiogenic agents, hormones, anesthetics, antimicrobial agents (antibacterial, antifungal, antiviral), anti-inflammatory agents, diagnostic agents, or wound healing agents. Similarly, low concentrations of dye (such as methylene blue) or fillers can be added to the inverse thermosensitive polymer.

The molecular weight of the inverse thermosensitive polymer may be between 1,000 and 50,000, or between 5,000 and 35,000. Typically the polymer is in an aqueous solution. For example, typical aqueous solutions contain about 5% to about 30% polymer, or about 10% to about 25%. The molecular weight of a suitable inverse thermosensitive polymer (such as a poloxamer or poloxamine) may be, for example, between 5,000 and 25,000, or between 7,000 and 20,000.

The pH of the inverse thermosensitive polymer formulation administered to the mammal is, generally, about 6.0 to about 7.8, which are suitable pH levels for injection into the mammalian body. The pH level may be adjusted by any suitable acid or base, such as hydrochloric acid or sodium hydroxide.

5 *Poloxamers (Pluronics)*

Notably, Pluronic<sup>®</sup> polymers have unique surfactant abilities and extremely low toxicity and immunogenic responses. These products have low acute oral and dermal toxicity and low potential for causing irritation or sensitization, and the general chronic and sub-chronic toxicity is low. In fact, Pluronic<sup>®</sup> polymers are among a small number of  
10 surfactants that have been approved by the FDA for direct use in medical applications and as food additives (BASF (1990) Pluronic<sup>®</sup> & Tetronic<sup>®</sup> Surfactants, BASF Co., Mount Olive, N.J.). Recently, several Pluronic<sup>®</sup> polymers have been found to enhance the therapeutic effect of drugs, and the gene transfer efficiency mediated by adenovirus. (March K L, Madison J E, Trapnell B C. "Pharmacokinetics of adenoviral vector-mediated gene  
15 delivery to vascular smooth muscle cells: modulation by poloxamer 407 and implication for cardiovascular gene therapy" *Hum Gene Therapy* **1995**, 6, 41-53).

Poloxamers (or Pluronics), as nonionic surfactants, are widely used in diverse industrial applications. (Nonionic Surfactants: polyoxyalkylene block copolymers, Vol. 60. Nace VM, Dekker M (editors), New York, 1996. 280 pp.) Their surfactant properties  
20 have been useful in detergency, dispersion, stabilization, foaming, and emulsification. (Cabana A, Abdellatif AK, Juhasz J. "Study of the gelation process of polyethylene oxide. polypropylene oxide-polyethylene oxide copolymer (poloxamer 407) aqueous solutions." *Journal of Colloid and Interface Science*. 1997; 190: 307-312.) Certain poloxamines, *e.g.*, poloxamine 1307 and 1107, also display inverse thermosensitivity.

25 Some of these polymers have been considered for various cardiovascular applications, as well as in sickle cell anemia. (Maynard C, Swenson R, Paris JA, Martin JS, Hallstrom AP, Cerqueira MD, Weaver WD. Randomized, controlled trial of RheothRx (poloxamer 188) in patients with suspected acute myocardial infarction. RheothRx in Myocardial Infarction Study Group. *Am Heart J*. 1998 May; 135 (5 Pt 1): 797-804; O'Keefe  
30 JH, Grines CL, DeWood MA, Schaer GL, Browne K, Magorien RD, Kalbfleisch JM, Fletcher WO Jr, Bateman TM, Gibbons RJ. Poloxamer-188 as an adjunct to primary percutaneous transluminal coronary angioplasty for acute myocardial infarction. *Am J Cardiol*. 1996 Oct 1;78(7):747-750; and Orringer EP, Casella JF, Ataga KI, Koshy M,

Adams-Graves P, Luchtman-Jones L, Wun T, Watanabe M, Shafer F, Kutlar A, Abboud M, Steinberg M, Adler B, Swerdlow P, Terregino C, Saccente S, Files B, Ballas S, Brown R, Wojtowicz-Praga S, Grindel JM. Purified poloxamer 188 for treatment of acute vasoocclusive crisis of sickle cell disease: A randomized controlled trial. JAMA. 2001 Nov 7;286 (17):2099-2106.)

Importantly, several members of this class of polymer, e.g., poloxamer 188, poloxamer 407, poloxamer 338, poloxamines 1107 and 1307, show inverse thermosensitivity within the physiological temperature range. (Qiu Y, Park K. Environment-sensitive hydrogels for drug delivery. *Adv Drug Deliv Rev.* 2001 Dec 31;53(3):321-339; and Ron ES, Bromberg LE Temperature-responsive gels and thermogelling polymer matrices for protein and peptide delivery *Adv Drug Deliv Rev.* 1998 May 4;31(3):197- 221.) In other words, these polymers are members of a class that are soluble in aqueous solutions at low temperature, but gel at higher temperatures. Poloxamer 407 is a biocompatible polyoxypropylene-polyoxyethylene block copolymer having an average molecular weight of about 12,500 and a polyoxypropylene fraction of about 30%; poloxamer 188 has an average molecular weight of about 8400 and a polyoxypropylene fraction of about 20%; poloxamer 338 has an average molecular weight of about 14,600 and a polyoxypropylene fraction of about 20 %; poloxamine 1,107 has an average molecular weight of about 14,000, poloxamine 1307 has an average molecular weight of about 18,000. Polymers of this type are also referred to as reversibly gelling because their viscosity increases and decreases with an increase and decrease in temperature, respectively. Such reversibly gelling systems are useful wherever it is desirable to handle a material in a fluid state, but performance is preferably in a gelled or more viscous state. As noted above, certain poly(ethyleneoxide)/poly(propyleneoxide) block copolymers have these properties; they are available commercially as Pluronic® poloxamers and Tetronic® poloxamines (BASF, Ludwigshafen, Germany) and generically known as poloxamers and poloxamines, respectively. See U.S. Pat. Nos. 4,188,373, 4,478,822 and 4,474,751 (all of which are incorporated by reference).

The average molecular weights of the poloxamers range from about 1,000 to greater than 16,000 Daltons. Because the poloxamers are products of a sequential series of reactions, the molecular weights of the individual poloxamer molecules form a statistical distribution about the average molecular weight. In addition, commercially available poloxamers contain substantial amounts of poly(oxyethylene) homopolymer and

poly(oxyethylene)/poly(oxypropylene diblock polymers. The relative amounts of these byproducts increase as the molecular weights of the component blocks of the poloxamer increase. Depending upon the manufacturer, these byproducts may constitute from about 15 to about 50% of the total mass of the polymer.

5 *Purification of Inverse Thermosensitive Polymers*

The inverse thermosensitive polymers may be purified using a process for the fractionation of water-soluble polymers, comprising the steps of dissolving a known amount of the polymer in water, adding a soluble extraction salt to the polymer solution, maintaining the solution at a constant optimal temperature for a period of time adequate for  
10 two distinct phases to appear, and separating physically the phases. Additionally, the phase containing the polymer fraction of the preferred molecular weight may be diluted to the original volume with water, extraction salt may be added to achieve the original concentration, and the separation process repeated as needed until a polymer having a narrower molecular weight distribution than the starting material and optimal physical  
15 characteristics can be recovered.

In certain embodiments, a purified poloxamer or poloxamine has a polydispersity index from about 1.5 to about 1.0. In certain embodiments, a purified poloxamer or poloxamine has a polydispersity index from about 1.2 to about 1.0.

The aforementioned process consists of forming an aqueous two-phase system  
20 composed of the polymer and an appropriate salt in water. In such a system, a soluble salt can be added to a single phase polymer-water system to induce phase separation to yield a high salt, low polymer bottom phase, and a low salt, high polymer upper phase. Lower molecular weight polymers partition preferentially into the high salt, low polymer phase. Polymers that can be fractionated using this process include polyethers, glycols such as  
25 poly(ethylene glycol) and poly(ethylene oxide)s, polyoxyalkylene block copolymers, such as poloxamers, poloxamines, and polyoxypropylene/ polyoxybutylene copolymers, and other polyols, such as polyvinyl alcohol. The average molecular weight of these polymers may range from about 800 to greater than 100,000 Daltons. See U.S. Patent 6,761,824 (incorporated by reference). The aforementioned purification process inherently exploits  
30 the differences in size and polarity, and therefore solubility, among the poloxamer molecules, the poly(oxyethylene) homopolymer and the poly(oxyethylene)/poly(oxypropylene) diblock byproducts. The polar fraction of the poloxamer, which generally includes the lower molecular weight fraction and the

byproducts, is removed allowing the higher molecular weight fraction of poloxamer to be recovered. The larger molecular weight purified poloxamer (an example of a purified inverse thermosensitive polymer) recovered by this method has physical characteristics substantially different from the starting material or commercially available poloxamer including a higher average molecular weight, lower polydispersity and a higher viscosity in aqueous solution.

Other purification methods may be used to achieve the desired outcome. For example, WO 92/16484 (incorporated by reference) discloses the use of gel permeation chromatography to isolate a fraction of poloxamer 188 that exhibits beneficial biological effects, without causing potentially deleterious side effects. The copolymer thus obtained had a polydispersity index of 1.07 or less, and was substantially saturated. The potentially harmful side effects were shown to be associated with the low molecular weight, unsaturated portion of the polymer, while the medically beneficial effects resided in the uniform higher molecular weight material. Other similarly improved copolymers were obtained by purifying either the polyoxypropylene center block during synthesis of the copolymer, or the copolymer product itself (*e.g.*, U.S. Pat. No. 5,523,492 and U.S. Pat. No. 5,696,298, both of which are incorporated by reference).

Further, a supercritical fluid extraction technique has been used to fractionate a polyoxyalkylene block copolymer as disclosed in U.S. Pat. No. 5,567,859 (incorporated by reference). A purified fraction was obtained, which was composed of a fairly uniform polyoxyalkylene block copolymer having a polydispersity of less than 1.17. According to this method, the lower molecular weight fraction was removed in a stream of carbon dioxide maintained at a pressure of 2200 pounds per square inch (psi) and a temperature of 40 °C.

Additionally, U.S. Pat. No. 5,800,711 (incorporated by reference) discloses a process for the fractionation of polyoxyalkylene block copolymers by the batchwise removal of low molecular weight species using a salt extraction and liquid phase separation technique. Poloxamer 407 and poloxamer 188 were fractionated by this method. In each case, a copolymer fraction was obtained which had a higher average molecular weight and a lower polydispersity index as compared to the starting material. However, the changes in polydispersity index were modest and analysis by gel permeation chromatography indicated that some low-molecular-weight material remained. The viscosity of aqueous solutions of the fractionated polymers was significantly greater than the viscosity of the commercially

available polymers at temperatures between 10 °C and 37 °C, an important property for some medical and drug delivery applications. Nevertheless, some of the low molecular weight contaminants of these polymers are thought to cause deleterious side effects when used inside the body, making it especially important that they be removed in the  
5 fractionation process. As a consequence, polyoxyalkylene block copolymers fractionated by this process are not appropriate for all medical uses.

As mentioned above, the use of these polymers in larger concentrations in humans requires removal of lower molecular weight contaminants present in commercial preparations. As was demonstrated in US Patent 5,567,859 (incorporated by reference;  
10 Examples 8 & 9), the lower molecular weight contaminants are mostly responsible for the toxic effects seen. In a clinical trial using unpurified poloxamer 188, an unacceptable level of transient renal dysfunction was found (Maynard C, Swenson R, Paris JA, Martin JS, Hallstrom AP, Cerqueira MD, Weaver WD. Randomized, controlled trial of RheothRx (poloxamer 188) in patients with suspected acute myocardial infarction. RheothRx in  
15 Myocardial Infarction Study Group. Am Heart J. 1998 May; 135(5 Pt 1):797-804), while another clinical trial using purified poloxamer 188 specifically mentioned that no renal dysfunction was found (Orringer EP, Casella JF, Ataga KI, Koshy M, Adams-Graves P, Luchtman-Jones L, Wun T, Watanabe M, Shafer F, Kutlar A, Abboud M, Steinberg M, Adler B, Swerdlow P, Terregino C, Saccente S, Files B, Ballas S, Brown R, Wojtowicz-  
20 Praga S, Grindel JM. Purified poloxamer 188 for treatment of acute vasoocclusive crisis of sickle cell disease: A randomized controlled trial. JAMA. 2001 Nov 7;286(17):2099-2106.) Therefore, it seems imperative to utilize only fractionated poloxamers and poloxamines in EMR applications like the ones envisioned here. Furthermore, fractionation of these thermosensitive polymers leads to improved gels with stronger mechanical resistance and  
25 due to the improved thermosensitivity requires less polymer to achieve gelation (See for example US patent No. 6,761,824 (incorporated by reference) on a purification scheme and the resultant viscosities).

#### *Drug Delivery in Conjunction with EMR Using Purified Inverse Thermosensitive Polymers*

Therapeutically effective use of many types of biologically active molecules has not  
30 been realized simply because methods are not available to effect delivery of therapeutically effective amounts of such substances into the particular cells of a patient for which treatment would provide therapeutic benefit. New ways of delivering drugs at the right

time, in a controlled manner, with minimal side effects, and greater efficacy per dose are sought by the drug-delivery and pharmaceutical industries.

The reversibly gelling polymers used in the EMR methods of the invention have physico-chemical characteristics that make them suitable delivery vehicles for conventional  
5 small-molecule drugs, as well as new macromolecular (*e.g.*, peptides) drugs or other therapeutic products. Therefore, the composition comprising the purified inverse thermosensitive polymer may further comprise a pharmaceutical agent selected to provide a pre-selected pharmaceutical effect. A pharmaceutical effect is one which seeks to treat the source or symptom of a disease or physical disorder. Pharmaceuticals include those products  
10 subject to regulation under the FDA pharmaceutical guidelines, as well as consumer products. Importantly, the compositions used EMR methods of the invention are capable of solubilizing and releasing bioactive materials. Solubilization is expected to occur as a result of dissolution in the bulk aqueous phase or by incorporation of the solute in micelles created by the hydrophobic domains of the poloxamer. Release of the drug would occur  
15 through diffusion or network erosion mechanisms.

Those skilled in the art will appreciate that the compositions used in the EMR methods of the invention may simultaneously be utilized to deliver a wide variety of pharmaceutical and personal care applications. To prepare a pharmaceutical composition, an effective amount of pharmaceutically active agent(s), which imparts the desirable  
20 pharmaceutical effect is incorporated into the reversibly gelling composition used in the EMR methods of the invention. Preferably, the selected agent is water soluble, which will readily lend itself to a homogeneous dispersion throughout the reversibly gelling composition. It is also preferred that the agent(s) is non-reactive with the composition. For materials, which are not water soluble, it is also within the scope of the EMR methods of the invention to  
25 disperse or suspend lipophilic material throughout the composition. Myriad bioactive materials may be delivered using the methods of the present invention; the delivered bioactive material includes anesthetics, antimicrobial agents (antibacterial, antifungal, antiviral), anti-inflammatory agents, diagnostic agents, and wound healing agents.

Because the reversibly gelling composition used in the methods of the present  
30 invention are suited for application under a variety of physiological conditions, a wide variety of pharmaceutically active agents may be incorporated into and administered from the composition. The pharmaceutical agent loaded into the polymer networks of the purified inverse thermosensitive polymer may be any substance having biological activity, including

proteins, polypeptides, polynucleotides, nucleoproteins, polysaccharides, glycoproteins, lipoproteins, and synthetic and biologically engineered analogs thereof.

A vast number of therapeutic agents may be incorporated in the polymers used in the methods of the present invention. In general, therapeutic agents which may be administered via the methods of the invention include, without limitation: antiinfectives such as antibiotics and antiviral agents; analgesics and analgesic combinations; anorexics; antihelmintics; antiarthritics; antiasthmatic agents; anticonvulsants; antidepressants; antidiuretic agents; antidiarrheals; antihistamines; antiinflammatory agents; antimigraine preparations; antinauseants; antineoplastics; antiparkinsonism drugs; antipruritics; antipsychotics; antipyretics, antispasmodics; anticholinergics; sympathomimetics; xanthine derivatives; cardiovascular preparations including calcium channel blockers and beta-blockers such as pindolol and antiarrhythmics; antihypertensives; diuretics; vasodilators including general coronary, peripheral and cerebral; central nervous system stimulants; cough and cold preparations, including decongestants; hormones such as estradiol and other steroids, including corticosteroids; hypnotics; immunosuppressives; muscle relaxants; parasympatholytics; psychostimulants; sedatives; and tranquilizers; and naturally derived or genetically engineered proteins, polysaccharides, glycoproteins, or lipoproteins. Suitable pharmaceuticals for parenteral administration are well known as is exemplified by the Handbook on Injectable Drugs, 6<sup>th</sup> Edition, by Lawrence A. Trissel, American Society of Hospital Pharmacists, Bethesda, Md., 1990.

The pharmaceutically active compound may be any substance having biological activity, including proteins, polypeptides, polynucleotides, nucleoproteins, polysaccharides, glycoproteins, lipoproteins, and synthetic and biologically engineered analogs thereof. The term "protein" is art-recognized and for purposes of this invention also encompasses peptides. The proteins or peptides may be any biologically active protein or peptide, naturally occurring or synthetic.

Examples of proteins include antibodies, enzymes, growth hormone and growth hormone-releasing hormone, gonadotropin-releasing hormone, and its agonist and antagonist analogues, somatostatin and its analogues, gonadotropins such as luteinizing hormone and follicle-stimulating hormone, peptide T, thyrocalcitonin, parathyroid hormone, glucagon, vasopressin, oxytocin, angiotensin I and II, bradykinin, kallidin, adrenocorticotrophic hormone, thyroid stimulating hormone, insulin, glucagon and the numerous analogues and congeners of the foregoing molecules. The pharmaceutical agents

may be selected from insulin, antigens selected from the group consisting of MMR (mumps, measles and rubella) vaccine, typhoid vaccine, hepatitis A vaccine, hepatitis B vaccine, herpes simplex virus, bacterial toxoids, cholera toxin B-subunit, influenza vaccine virus, bordetella pertussis virus, vaccinia virus, adenovirus, canary pox, polio vaccine virus, plasmodium falciparum, bacillus calmette geurin (BCG), klebsiella pneumoniae, HIV envelop glycoproteins and cytokins and other agents selected from the group consisting of bovine somatropine (sometimes referred to as BST), estrogens, androgens, insulin growth factors (sometimes referred to as IGF), interleukin I, interleukin II and cytokins. Three such cytokins are interferon- $\beta$ , interferon- $\gamma$  and tuftsin.

10           Examples of bacterial toxoids that may be incorporated in the compositions used in the EMR methods of the invention are tetanus, diphtheria, pseudomonas A, mycobacterium tuberculosis. Examples of that may be incorporated in the compositions used in the EMR methods of the invention are HIV envelope glycoproteins, *e.g.*, gp 120 or gp 160, for AIDS vaccines. Examples of anti-ulcer H2 receptor antagonists that may be included are  
15 ranitidine, cimetidine and famotidine, and other anti-ulcer drugs are omeprazole, esomeprazole and misoprostol. An example of a hypoglycaemic agent is glipizide.

          Classes of pharmaceutically active compounds which can be loaded into that may be incorporated in the compositions used in the EMR methods of the invention include, but are not limited to, anti-AIDS substances, anti-cancer substances, antibiotics,  
20 immunosuppressants (*e.g.*, cyclosporine) anti-viral substances, enzyme inhibitors, neurotoxins, opioids, hypnotics, antihistamines, lubricants tranquilizers, anti-convulsants, muscle relaxants and anti-Parkinson substances, anti-spasmodics and muscle contractants, miotics and anti-cholinergics, anti-glaucoma compounds, anti-parasite and/or anti-protozoal compounds, anti-hypertensives, analgesics, anti-pyretics and anti-inflammatory agents such  
25 as NSAIDs, local anesthetics, ophthalmics, prostaglandins, anti-depressants, anti-psychotic substances, anti-emetics, imaging agents, specific targeting agents, neurotransmitters, proteins, cell response modifiers, and vaccines.

          Exemplary pharmaceutical agents considered to be particularly suitable for incorporation in the compositions used in the EMR methods of the invention include but are  
30 not limited to imidazoles, such as miconazole, econazole, terconazole, saperconazole, itraconazole, metronidazole, fluconazole, ketoconazole, and clotrimazole, luteinizing-hormone-releasing hormone (LHRH) and its analogues, nonoxynol-9, a GnRH agonist or antagonist, natural or synthetic progestin, such as selected progesterone, 17-

hydroxyprogesterone derivatives such as medroxyprogesterone acetate, and 19-nortestosterone analogues such as norethindrone, natural or synthetic estrogens, conjugated estrogens, estradiol, estropipate, and ethinyl estradiol, bisphosphonates including etidronate, alendronate, tiludronate, resedronate, clodronate, and pamidronate, calcitonin, 5 parathyroid hormones, carbonic anhydrase inhibitor such as felbamate and dorzolamide, a mast cell stabilizer such as xesterbergsterol-A, lodoxamine, and cromolyn, a prostaglandin inhibitor such as diclofenac and ketorolac, a steroid such as prednisolone, dexamethasone, fluromethylone, rimexolone, and lotepednol, an antihistamine such as antazoline, pheniramine, and histaminase, pilocarpine nitrate, a beta-blocker such as levobunolol and 10 timolol maleate. As will be understood by those skilled in the art, two or more pharmaceutical agents may be combined for specific effects. The necessary amounts of active ingredient can be determined by simple experimentation.

By way of example only, any of a number of antibiotics and antimicrobials may be included in the purified inverse thermosensitive polymers used in the methods of the 15 invention. Antimicrobial drugs preferred for inclusion in compositions used in the EMR methods of the invention include salts of lactam drugs, quinolone drugs, ciprofloxacin, norfloxacin, tetracycline, erythromycin, amikacin, triclosan, doxycycline, capreomycin, chlorhexidine, chlortetracycline, oxytetracycline, clindamycin, ethambutol, hexamidine isethionate, metronidazole, pentamidine, gentamicin, kanamycin, lineomycin, 20 methacycline, methenamine, minocycline, neomycin, netilmicin, paromomycin, streptomycin, tobramycin, miconazole and amantadine and the like.

By way of example only, in the case of anti-inflammation, non-steroidal anti-inflammatory agents (NSAIDS) may be incorporated in the compositions used in the EMR methods of the invention, such as propionic acid derivatives, acetic acid, fenamic acid 25 derivatives, biphenylcarboxylic acid derivatives, oxicams, including but not limited to aspirin, acetaminophen, ibuprofen, naproxen, benoxaprofen, flurbiprofen, fenbufen, ketoprofen, indoprofen, piroprofen, carprofen, and bucloxic acid and the like.

#### *Exemplification*

The invention now being generally described, it will be more readily understood by 30 reference to the following examples, which are included merely for purposes of illustration of certain aspects and embodiments of the present invention, and are not intended to limit the invention.

#### Ex Vivo

Gastric endoscopic mucosal resections (120) were performed in fresh *ex vivo* porcine stomachs using three different solutions: normal saline solution (n = 40); HPMC (n = 40); and LeGoo-endo<sup>TM</sup> (n = 40). Each submucosal injection was performed by injecting 5 mL of solution by using a 10-mL syringe with a 25-gauge needle. After creating a visually adequate submucosal elevation, the needle was kept in position for a short time to block the puncture site and prevent premature escape of solution. The stomachs were placed on a thermal pad for assuring a constant temperature (35-37° C). In all cases, the height and size of the bleb and the duration of the submucosal elevation were measured. When the elevation lasted visible in place 120 minutes, the test was finished.

The height of initial mucosal elevations was higher with LeGoo-endo<sup>TM</sup> ( $10.3 \pm 2.2$  mm) than with saline ( $8.3 \pm 2.6$  mm,  $p < 0.01$ ) and HPMC ( $9.05 \pm 2.3$  mm,  $p = \text{ns}$ ). No significant differences were observed regarding the large diameter of the elevations between LeGoo-endo<sup>TM</sup> ( $34.7 \pm 4.4$  mm) and saline ( $36.7 \pm 4$  mm) or HPMC ( $33.7 \pm 4$  mm). All the submucosal elevations with LeGoo-endo<sup>TM</sup> lasted more than 120 minutes and the time was longer than with saline ( $20.9 \pm 11$  min,  $p < 0.01$ ) and HPMC ( $89 \pm 32$  min,  $p < 0.01$ ). After 120 minutes in place, the elevations performed with LeGoo-endo<sup>TM</sup> showed no differences in size, shape and consistency.

#### In Vivo

Five EMR were performed in the colon of 2 pigs with LeGoo-endo<sup>TM</sup> using a 23-gauge sclerotherapy needle with a 5-mL syringe and a balloon dilator gun. LeGoo-endo<sup>TM</sup> was kept on ice during the intervention. Saline containing syringes were also kept on ice to cool the catheter immediately before poloxamer injections. After creating a visually adequate submucosal elevation, it was assessed as “small”, “medium” or “big”. Then, an “en bloc” resection of the lesion was performed using a needle knife or a polypectomy snare. All procedures were recorded and pictures were taken. In all cases, the size of the resected specimen was measured and surfaces were assessed by histologic evaluation.

The five EMR were located in the sigma between 18 and 25 cm from the anus margin. The height of initial mucosal elevation was large in 2 cases, medium in 2 cases, and small in 1 case. After the injection of the polymer, no reposition was needed. The mean volume injected was  $6 \pm 2.5$  mL (range, 3-10 mL) and the mean size of the specimen resected was  $2.6 \pm 1.1$  cm (range 0.9-4 cm). The mean time for the resection was  $5 \pm 2$  minutes (range, 2-8 minutes). During the resection, a large amount of gel was observed between the submucosa and the mucosa. No thermal injury was observed in the serosa

surface and no perforations were reported. No changes were needed to electrocautery settings. In one case, a temporary bleeding from a submucosal vessel was observed. Histologic examination showed that submucosa layer was present in all the specimens.

**Equivalents**

- 5           Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.

We Claim:

1. Use of a composition comprising a purified inverse thermosensitive polymer in an endoscopic procedure for gastrointestinal mucosal resectioning in a mammal.
2. The use of claim 1, wherein said purified inverse thermosensitive polymer is a polyoxyalkylene block copolymer.
3. The use of claim 1, wherein said purified inverse thermosensitive polymer is selected from the group consisting of poloxamers and poloxamines.
4. The use of claim 1, wherein said purified inverse thermosensitive polymer is selected from the group consisting of poloxamer 407, poloxamer 338, poloxamer 118, poloxamer 237, Tetronic<sup>®</sup> 1107 and Tetronic<sup>®</sup> 1307.
5. The use of claim 1, wherein said purified inverse thermosensitive polymer is poloxamer 407.
6. The use of claim 1, wherein said purified inverse thermosensitive polymer is poloxamer 237.
7. The use of claim 1, wherein said composition has a transition temperature between about 10 °C and about 40 °C.
8. The use of claim 1, wherein said composition has a transition temperature between about 15 °C and about 30 °C.
9. The use of claim 1, wherein the volume of said composition at physiological temperature is about 80% to about 120% of its volume below its transition temperature.
10. The use of claim 1, wherein the volume of said composition at physiological temperature is about 80% to about 120% of its volume below its transition temperature; and said composition has a transition temperature between about 10 °C and about 40 °C.
11. The use of claim 1, wherein the volume of said composition at physiological temperature is about 80% to about 120% of its volume below its transition temperature; and said composition has a transition temperature between about 15 °C and about 30 °C.
12. The use of claim 1, wherein the volume of said composition at physiological temperature is about 80% to about 120% of its volume below its transition temperature; said composition has a transition temperature between about 10 °C and about 40 °C; and said purified inverse thermosensitive polymer is selected from the group consisting of poloxamers and poloxamines.
13. The use of claim 1, wherein the volume of said composition at physiological temperature is about 80% to about 120% of its volume below its transition temperature;

said composition has a transition temperature between about 15 °C and about 30 °C; and said purified inverse thermosensitive polymer is selected from the group consisting of poloxamers and poloxamines

14. The use of claim 1, wherein said composition comprises about 5% to about 35% of said purified inverse thermosensitive polymer.

15. The use of claim 1, wherein said composition comprises about 10% to about 30% of said purified inverse thermosensitive polymer.

16. The use of claim 1, wherein said purified inverse thermosensitive polymer has a polydispersity index from about 1.5 to about 1.0.

17. The use of claim 1, wherein said purified inverse thermosensitive polymer has a polydispersity index from about 1.2 to about 1.0.

18. The use of claim 1, wherein said composition further comprises a contrast-enhancing agent.

19. The use of claim 18, wherein said contrast-enhancing agent is selected from the group consisting of radiopaque materials, paramagnetic materials, heavy atoms, transition metals, lanthanides, actinides, dyes, and radionuclide-containing materials.

20. The use of any one of claims 1-19, wherein said mammal is a human.

21. A method of gastrointestinal mucosal resectioning, comprising administering submucosally to a region of a gastrointestinal mucosa in a mammal an effective amount of a composition comprising a purified inverse thermosensitive polymer; and surgically resecting said region of gastrointestinal mucosa.

22. The method of claim 21, wherein said purified inverse thermosensitive polymer is a polyoxyalkylene block copolymer.

23. The method of claim 21, wherein said purified inverse thermosensitive polymer is selected from the group consisting of poloxamers and poloxamines.

24. The method of claim 21, wherein said purified inverse thermosensitive polymer is selected from the group consisting of poloxamer 407, poloxamer 338, poloxamer 118, poloxamer 237, Tetronic<sup>®</sup> 1107 and Tetronic<sup>®</sup> 1307.

25. The method of claim 21, wherein said purified inverse thermosensitive polymer is poloxamer 407.

26. The method of claim 21, wherein said purified inverse thermosensitive polymer is poloxamer 237.

27. The method of claim 21, wherein said composition has a transition temperature between about 10 °C and about 40 °C.
28. The method of claim 21, wherein said composition has a transition temperature between about 15 °C and about 30 °C.
- 5 29. The method of claim 21, wherein the volume of said composition at physiological temperature is about 80% to about 120% of its volume below its transition temperature.
30. The method of claim 21, wherein the volume of said composition at physiological temperature is about 80% to about 120% of its volume below its transition temperature; and said composition has a transition temperature between about 10 °C and about 40 °C.
- 10 31. The method of claim 21, wherein the volume of said composition at physiological temperature is about 80% to about 120% of its volume below its transition temperature; and said composition has a transition temperature between about 15 °C and about 30 °C.
32. The method of claim 21, wherein the volume of said composition at physiological temperature is about 80% to about 120% of its volume below its transition temperature; and said composition has a transition temperature between about 10 °C and about 40 °C; and said purified inverse thermosensitive polymer is selected from the group consisting of poloxamers and poloxamines.
- 15 33. The method of claim 21, wherein the volume of said composition at physiological temperature is about 80% to about 120% of its volume below its transition temperature; said composition has a transition temperature between about 15 °C and about 30 °C; and said purified inverse thermosensitive polymer is selected from the group consisting of poloxamers and poloxamines
- 20 34. The method of claim 21, wherein said composition comprises about 5% to about 35% of said purified inverse thermosensitive polymer.
- 25 35. The method of claim 21, wherein said composition comprises about 10% to about 30% of said purified inverse thermosensitive polymer.
36. The method of claim 21, wherein said purified inverse thermosensitive polymer has a polydispersity index from about 1.5 to about 1.0.
37. The method of claim 21, wherein said purified inverse thermosensitive polymer has a polydispersity index from about 1.2 to about 1.0.
- 30 38. The method of claim 21, wherein said composition further comprises a contrast-enhancing agent.

39. The method of claim 38, wherein said contrast-enhancing agent is selected from the group consisting of radiopaque materials, paramagnetic materials, heavy atoms, transition metals, lanthanides, actinides, dyes, and radionuclide-containing materials.
40. The method of any one of claims 21-39, wherein said mammal is a human.
- 5 41. A kit for use in gastrointestinal endoscopic mucosal resectioning in a mammal, comprising a composition comprising a purified inverse thermosensitive polymer; a syringe; and instructions for use thereof.
42. The kit of claim 41, wherein said purified inverse thermosensitive polymer is a polyoxyalkylene block copolymer.
- 10 43. The kit of claim 41, wherein said purified inverse thermosensitive polymer is selected from the group consisting of poloxamers and poloxamines.
44. The kit of claim 41, wherein said purified inverse thermosensitive polymer is selected from the group consisting of poloxamer 407, poloxamer 338, poloxamer 118, poloxamer 237, Tetronic<sup>®</sup> 1107 and Tetronic<sup>®</sup> 1307.
- 15 45. The kit of claim 41, wherein said purified inverse thermosensitive polymer is poloxamer 407.
46. The kit of claim 41, wherein said purified inverse thermosensitive polymer is poloxamer 237.
47. The kit of claim 41, wherein said composition has a transition temperature between  
20 about 10 °C and about 40 °C.
48. The kit of claim 41, wherein said composition has a transition temperature between about 15 °C and about 30 °C.
49. The kit of claim 41, wherein the volume of said composition at physiological temperature is about 80% to about 120% of its volume below its transition temperature.
- 25 50. The kit of claim 41, wherein the volume of said composition at physiological temperature is about 80% to about 120% of its volume below its transition temperature; and said composition has a transition temperature between about 10 °C and about 40 °C.
51. The kit of claim 41, wherein the volume of said composition at physiological temperature is about 80% to about 120% of its volume below its transition temperature; and  
30 said composition has a transition temperature between about 15 °C and about 30 °C.
52. The kit of claim 41, wherein the volume of said composition at physiological temperature is about 80% to about 120% of its volume below its transition temperature; said composition has a transition temperature between about 10 °C and about 40 °C; and

said purified inverse thermosensitive polymer is selected from the group consisting of poloxamers and poloxamines.

53. The kit of claim 41, wherein the volume of said composition at physiological temperature is about 80% to about 120% of its volume below its transition temperature;
- 5 said composition has a transition temperature between about 15 °C and about 30 °C; and said purified inverse thermosensitive polymer is selected from the group consisting of poloxamers and poloxamines
54. The kit of claim 41, wherein said composition comprises about 5% to about 35% of said purified inverse thermosensitive polymer.
- 10 55. The kit of claim 41, wherein said composition comprises about 10% to about 30% of said purified inverse thermosensitive polymer.
56. The kit of claim 41, wherein said purified inverse thermosensitive polymer has a polydispersity index from about 1.5 to about 1.0.
57. The kit of claim 41, wherein said purified inverse thermosensitive polymer has a
- 15 polydispersity index from about 1.2 to about 1.0.
58. The kit of claim 41, wherein said composition further comprises a contrast-enhancing agent.
59. The kit of claim 58, wherein said contrast-enhancing agent is selected from the group consisting of radiopaque materials, paramagnetic materials, heavy atoms, transition
- 20 metals, lanthanides, actinides, dyes, and radionuclide-containing materials.
60. The kit of any one of claims 41-59, wherein said mammal is a human.

Figure 1





Figure 2



INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US 08/85114

A. CLASSIFICATION OF SUBJECT MATTER  
IPC(8) - A61B 18/18 (2009.01)  
USPC - 606/45  
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED  
Minimum documentation searched (classification system followed by classification symbols)  
IPC(8) - A61B 18/18 (2009.01)  
USPC - 606/45

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched  
IPC(8) - A61B 18/18 (2009.01) (text search only - see search history printout)  
USPC - 606/45 (text search only - see search history printout)

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
(USPT, PGPB, EPAB, JPAB); Google Patent, Google Scholar, Dialog Web  
endoscopic mucosal resectioning, emr, thermosensitive, thermoresponsive, thermoreversible, poloxamine, poloxamer, pluronic, tetronic, submucosal, polydispersity, transition temperature, volume, legoo, poloxamer 407, poloxamer 237, physiologically, kit

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category*       | Citation of document, with indication, where appropriate, of the relevant passages   | Relevant to claim No.   |
|-----------------|--|---|
| X<br>-----<br>Y | US 2006/0070631 A1 (Scopton et al.) 06 Apr 2006 (06.04.2006) (para [0002], [0030], [0031], [0034], [0035], [0042], [0049]).                  | 1-5, 14-15, 18-25, 34-35, 38-45, 54-55, 58-60<br>-----<br>6-13, 16-17, 26-33, 36-37, 46-53, 56-57 |
| Y               | US 2006/0013883 A1 (Nicol et al.) 19 Jan 2006 (19.01.2006) (Abstract, [0081], [0191], [0194]).   | 6, 26, 46   |
| Y               | US 2005/0147585 A1 (Schwarz) 07 Jul 2005 (07.07.2005) (para [0021], [0022], [0023], [0024], [0025], [0026], [0027], [0028], [0031], [0032]). | 7-13, 16-17, 27-33, 36-37, 47-53, 56-57   |

Further documents are listed in the continuation of Box C.

\* Special categories of cited documents:  
 "A" document defining the general state of the art which is not considered to be of particular relevance  
 "E" earlier application or patent but published on or after the international filing date  
 "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)  
 "O" document referring to an oral disclosure, use, exhibition or other means  
 "P" document published prior to the international filing date but later than the priority date claimed  
 "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention  
 "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone  
 "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art  
 "&" document member of the same patent family

Date of the actual completion of the international search  
08 Jan 2009 (08.01.2009)

Date of mailing of the international search report  
**26 JAN 2009**

Name and mailing address of the ISA/US  
Mail Stop PCT, Attn: ISA/US, Commissioner for Patents  
P.O. Box 1450, Alexandria, Virginia 22313-1450  
Facsimile No. 571-273-3201

Authorized officer  
*Lee W. Young*  
Lee W. Young  
PCT Helpdesk: 571-272-4300  
PCT OSP: 571-272-7774